Management for motor and non-motor complications in late Parkinson's disease

Geriatrics

Volumn 63, Issue 5, 2008, Pages 22-27

  Chan, Daniel K Y ^a,b   Cordato, Dennis J ^c   O'Rourke, Fintan ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

Author keywords

Motor complications; Non motor complications; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT DERIVATIVE; FLUDROCORTISONE; HALOPERIDOL; LEVODOPA; MIDODRINE; MONOAMINE OXIDASE B INHIBITOR; OLANZAPINE; PERGOLIDE; PINDOLOL; PRAMIPEXOLE; PROPRANOLOL; PYRIDOSTIGMINE; QUETIAPINE; RASAGILINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; TOLCAPONE; UNINDEXED DRUG;

AGING; AGRANULOCYTOSIS; ASPIRATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; DYSPHAGIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FALLING; FIBROSIS; HALLUCINATION; HUMAN; HYPOTENSION; INSOMNIA; KIDNEY FIBROSIS; LOW DRUG DOSE; LUNG DISEASE; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PREVALENCE; PSYCHOSIS; REHABILITATION CARE; RETROPERITONEAL DISEASE; REVIEW; SLEEP DISORDER; SOMNOLENCE; SURGICAL TECHNIQUE; TREATMENT PLANNING; VALVULAR FIBROSIS; VALVULAR HEART DISEASE; VALVULAR REGURGITATION;

ACCIDENTAL FALLS; AGED; ANTIPARKINSON AGENTS; COMORBIDITY; DEMENTIA; DYSKINESIAS; HUMANS; HYPOTENSION, ORTHOSTATIC; LEVODOPA; PARKINSON DISEASE; SLEEP DISORDERS;

EID: 44849103691     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Chan DK, Cordato D, Bui T, Mellick G, Woo J. Comparison of environmental and genetic factors for Parkinson's disease between Chinese and Caucasians. Neuroepidemiology. 2004;23(1-2):13-22.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobio Aging. 2003;24(2):197-211.
3. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol. 2000;247(suppl 2):II3-II10.
4. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care. London: NICE, 2006. Available online at: http://guidance.nice.org.uk/CG35. Accessed April 9, 2008.
5. Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol. 2. Florham Park, NJ: Macmillan Health Care Information, 1987:153-163, 293-304.
6. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-1053.
7. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994;57(8):903-910.
8. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356(1):39-46.
9. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004;(4):CD004554.
10. Rascol O, Brooks DJ, Melamed E, et al, for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954.
11. Jakovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-692.
12. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2008 Jan 7 (epub ahead of print).
13. Kern DS, Kumar R. Deep brain stimulation. Neurologist. 2007;13(5):237-252.
14. Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection for deep brain stimulation. Neurologist. 2007;13(5):253-260.
15. Deuschl G, Schade-Brittinger C, Krack P et al, for the German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
16. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509- 2518.
17. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708-712.
18. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56(6):730-736.
19. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003;2(4):229-237.
20. Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol. 2003;60(4):539-544.
21. Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregration in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 2003;4(1-2):21-36.
22. Lashley T, Holton JL, Gray E, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008;115(4):417-425.
23. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1999;340(10):757-763.
24. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet. 1999;353(9169):2041-2042.
25. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513-518.
26. Chan DKY. Falls. In: Chan DKY, ed. CHAN'S PRACTICAL GERIATRICS. Brookvale, NSW, Australia: BA Printing & Publishing Services; 2006:55. Available online at: www.chanspracticalgeriatrics.com.au. Accessed April 9, 2008.
27. Chan D, Phoon S, Yeoh E. Australian Society for Geriatric Medicine, Position Statement No. 12: Dysphagia and aspiration in older people. April 26, 2004. Available online at: http://www.asgm.org.au/documents/ PositionStatementNo12-DysphagiaAspiration.pdf. Accessed March 26, 2008.
28. Chan DKY. Insomnia. In: Chan DKY, ed. CHAN'S PRACTICAL GERIATRICS. Brookvale, NSW, Australia: BA Printing & Publishing Services; 2006:200-204.